Home LiteratureArticle Details
PMID: 10415074 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 163 ·No. 3 ·1999-08-01 ·Pages 1674-81

Reijonen H, Elliott JF, van Endert P, Nepom G

Abstract

Glutamic acid decarboxylase 65 (GAD65) is one of the major autoantigens in type 1 diabetes. We investigated whether there is variation in the processing of GAD65 epitopes between individuals with similar HLA backgrounds and whether the processing characteristics of certain immunogenic epitopes are different in distinct APC subpopulations. Using DR401-restricted T cell hybridomas specific for two immunogenic GAD65 epitopes (115-127 and 274-286), we demonstrate an epitope-specific presentation pattern in human B-lymphoblastoid cell lines (B-LCL). When pulsed with the GAD protein, some DRB1*0401-positive B-LCL, which presented GAD65 274-286 epitope efficiently, were unable to present the GAD65 115-127 epitope. However, all B-LCL presented synthetic peptides corresponding to either GAD epitope. In addition, when pulsed with human serum albumin, all cell lines gave equal stimulation of a DR4-restricted human serum albumin-specific T hybridoma. GAD65-transfected cell lines displayed the same presentation phenotype, showing that lack of the presentation of the 115-127 epitope was not due to inefficient uptake of the protein. Blood mononuclear adherent cells, B cells, or dendritic cells derived from the same individual displayed the same presentation pattern as observed in B cell lines, suggesting that the defect most likely is genetically determined. Therefore, individual differences in Ag processing may result in the presentation of distinct set of peptides derived from an autoantigen such as GAD65. This may be an important mechanism for the deviation of the immune response either into a regulatory pathway or into an inflammatory autoimmune reactivity.

MeSH Terms
Antigen Presentation/drug effects Antigen-Presenting Cells/drug effects,enzymology,metabolism B-Lymphocytes/drug effects,immunology,metabolism Cell Line, Transformed Cell Lineage/immunology Epitopes, T-Lymphocyte/immunology,metabolism Glutamate Decarboxylase/antagonists & inhibitors,immunology,metabolism HLA-DR Antigens/immunology,metabolism HLA-DRB1 Chains Humans Leupeptins/pharmacology Lymphocyte Activation Pepstatins/pharmacology Protease Inhibitors/pharmacology Transfection
Chemicals
Epitopes, T-Lymphocyte HLA-DR Antigens HLA-DRB1 Chains HLA-DRB1*04:01 antigen Leupeptins Pepstatins Protease Inhibitors Streptomyces pepsin inhibitor Glutamate Decarboxylase leupeptin pepstatin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Reijonen H
Virginia Mason Research Center, Seattle, WA 98101, USA. reijonen@vmresearch.org
Elliott J F
van Endert P
Nepom G
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
1999-08-01
Pages
1674-81
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Grants
NIAID NIH HHS · AI 38913 · United States
NIDDK NIH HHS · DK49841 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com